Patents Examined by James W. Rogers
-
Patent number: 11826485Abstract: One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer.Type: GrantFiled: April 23, 2021Date of Patent: November 28, 2023Assignee: HyperBranch Medical Technology, Inc.Inventors: Kenneth E. Stockman, Michael A. Carnahan, Keith R. D'Alessio, Mark W. Grinstaff
-
Patent number: 11793893Abstract: A compound comprising an oligomer formed from a biocompatible multifunctional carboxylic acid comprising a hydroxyl group and at least one carboxylic acid, an polyol (e.g., an aliphatic diol), and a linker. One or more conductive oligomers (e.g., polyanilines) are covalently bonded to the oligomer. The compounds can have various forms (e.g., articles of manufacture, films, scaffolds, and the like). The compounds have various uses. For example, the compounds are used in photoacoustic imaging methods.Type: GrantFiled: October 3, 2017Date of Patent: October 24, 2023Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Jian Yang, Dingying Shan
-
Patent number: 11793909Abstract: The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for controlling the movement of bodily fluid within a patient, among many other uses.Type: GrantFiled: March 21, 2022Date of Patent: October 24, 2023Assignee: Medtronic Vascular, Inc.Inventors: Craig Wiltsey, Nikhita Mansukhani, Jeffrey Groom, II, Kate Rielly, Changcheng You, Danny Concagh
-
Patent number: 11779646Abstract: The present disclosure features a protein-polymer conjugate, including a multivalent polymer building block, a stimuli-responsive protein covalently conjugated to the multivalent polymer building block to provide a protein-polymer conjugate, wherein the protein undergoes a modification upon exposure to a predetermined stimulus, and the protein modification triggers a physical and/or chemical response in the protein-polymer conjugate.Type: GrantFiled: April 30, 2019Date of Patent: October 10, 2023Assignee: University of WashingtonInventors: Cole Alexander DeForest, Jared Shadish, Luman Liu
-
Patent number: 11779661Abstract: The present disclosure provides nucleic acid binding nanoprobes having one or more fluorochromes and a polymer, where each of the fluorochromes is connected to the polymer, and methods of using the same.Type: GrantFiled: November 8, 2017Date of Patent: October 10, 2023Assignee: The General Hospital CorporationInventors: David Sosnovik, Lee Josephson, Howard Chen
-
Patent number: 11752221Abstract: Disclosed are methods, compositions, reagents, systems, and kits to prepare nitroxide-functionalized brush-arm star polymer organic radical contrast agent (BASP-ORCA) as well as compositions and uses thereof. Various embodiments show that BASP-ORCA display unprecedented per-nitroxide and per-molecule transverse relaxivities for organic radical contrast agents, exceptional stability, high water solubility, low in vitro and in vivo toxicity, and long blood compartment half-life. These materials have the potential to be adopted for tumor imaging using clinical high-field 1H MRI techniques.Type: GrantFiled: June 29, 2018Date of Patent: September 12, 2023Assignees: Massachusetts Institute of Technology, Board of Regents of the University of NebraskaInventors: Jeremiah A. Johnson, Hung Vanthanh Nguyen, Andrzej Rajca
-
Patent number: 11752250Abstract: The invention concerns methods of treating blood, blood product, or physiologic fluid to provide at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; said method comprising contacting said blood, blood product or physiologic fluid with a sorbent, said sorbent being primarily in a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of at least one of (1) zwitterionic moieties and (2) oligo(ethylene glycol) moieties attached to the surface of said cross-linked polymeric material.Type: GrantFiled: March 31, 2014Date of Patent: September 12, 2023Assignee: CytoSorbents CorporationInventors: Thomas D. Golobish, Vincent J. Capponi, David R. Clay
-
Patent number: 11744916Abstract: The present disclosure relates to radiopaque PVA polymers where the PVA has a first pendant group and a second pendant group, wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodine atoms, and the second pendant group comprises either (a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group. Each W is selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C?O)—O—C1-4alkyl and —O—(C?O)C1-4alkyl; wherein R1 is H or C1-4 alkyl; R2 is —COOH, —SO3H, or —OPO3H2; q is an integer from 1 to 4; wherein the group W may be in the form of a pharmaceutically acceptable salt; or (b) a pyridyl group; which is optionally in the form of a pyridinium ion.Type: GrantFiled: July 20, 2020Date of Patent: September 5, 2023Inventors: Koorosh Ashrafi, Hugh Britton, Francesco Cuda, Andrew Lennard Lewis, Cristian Parisi, Yiqing Tang, Sean Leo Willis
-
Patent number: 11744903Abstract: A method for preparing a cyclodextrin metal organic framework (CD-MOF) stable in aqueous phase, including: dissolving ?-cyclodextrin and solid potassium hydroxide in deionized water followed by magnetic stirring and ultrasonic treatment at room temperature, addition of methanol and stirring to obtain a reaction mixture; filtering the reaction mixture with a polytetrafluoroethylene membrane filter in a beaker; placing the beaker in methanol vapor to form a ?-CD-MOF crystal; washing the ?-CD-MOF crystal with ethanol followed by centrifugation and vacuum drying to obtain ?-CD-MOF; preparing a ?-CD-MOF-active substance complex by impregnation; and preparing an active substance-loaded ?-CD-MOF-Tween 80 complex by physical adsorption modification followed by washing with anhydrous ethanol and vacuum drying.Type: GrantFiled: March 22, 2023Date of Patent: September 5, 2023Assignee: Qilu University of TechnologyInventors: Chao Yuan, Bo Cui, Meng Zhao, Lu Lu, Jianpeng Li, Yaqi Liu
-
Patent number: 11723984Abstract: The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.Type: GrantFiled: November 29, 2018Date of Patent: August 15, 2023Assignee: NOVELTY NOBILITY INC.Inventors: Tae Hyeon Yoo, Jisoo Park, Yumi Lee
-
Patent number: 11702498Abstract: A hydrophilic polymer comprising pendent groups of the formula I: Wherein: W is independently selected from —OH, —COOH, —SO3H, —OPO3H, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C?O)—O—C1-4alkyl and —O—(C?O)C1-4alkyl; or a group —BZ; wherein —OH, COOH, O—PO3H and SO3H maybe in the form of a pharmaceutically acceptable salt; wherein: B is a bond, or a straight branched alkanediyl, oxyalkylene, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and Z is an ammonium, phosphonium, or sulphonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; G is a coupling group through which the group of the formula I is coupled to the polymer and is selected from ether, ester, amide, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane; R1 is H or C1-4 alkyl; R2 is —COOH, —SO3H, or —OPO3H2 q is an integer from 1 to 4;Type: GrantFiled: June 26, 2019Date of Patent: July 18, 2023Inventors: Andrew Lennard Lewis, Hugh Britton, Yiqing Tang, Jonathan Vince, Koorosh Ashrafi, Damien Guegan
-
Patent number: 11696953Abstract: Provided herein are branched poly(beta-amino esters) (PBAE) useful as vehicles for the delivery of therapeutic agents, such as nucleic acids. The disclosed polymers form stable compositions, and are suitable for the delivery of therapeutic agents via nebulization. Compositions of the disclosed polymers are capable of delivering therapeutic agents such as mRNA to lung epithelial cells.Type: GrantFiled: September 7, 2022Date of Patent: July 11, 2023Assignee: Massachusetts Institute of TechnologyInventors: Daniel Griffith Anderson, Kevin John Kauffman, James C. Kaczmarek, Asha Kumari Patel
-
Patent number: 11691997Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: GrantFiled: April 1, 2015Date of Patent: July 4, 2023Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
-
Patent number: 11691976Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.Type: GrantFiled: August 22, 2019Date of Patent: July 4, 2023Assignee: Promega CorporationInventors: Joel R. Walker, Thomas A. Kirkland, Wenhui Zhou, Mary P. Hall, Harry Tetsuo Uyeda
-
Patent number: 11672888Abstract: Methods for generating porous scaffolds may include tuning a porogen/crystallite's particle size to a desired range and mixing the crystallite particles with a polymer solution. The mixture is then cast to form films. The films are rolled and consolidated around another inner material to create a preform, which is then thermally drawn. The inner material and the porogen can be selectively removed to obtain porous constructs/fibers. The structures can be fuse-printed to produce complex tissue scaffolds with dimensions up to several centimeters and beyond.Type: GrantFiled: November 26, 2019Date of Patent: June 13, 2023Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Polina Olegovna Anikeeva, Dena Shahriari, Yoel Fink, Zi Jie Gabriel Loke, Ian James Tafel
-
Patent number: 11672867Abstract: The invention provides polymers and polymer-based nano-structures, in particular, polymers and polymer network to which biomolecules (e.g., proteins, antibodies, peptide aptamers) can be covalently conjugated and stably encapsulated therein and be controllably delivered and released upon degradation of the nano-structures in response to specific microenvironment, and compositions and methods of preparation and use thereof.Type: GrantFiled: March 30, 2018Date of Patent: June 13, 2023Assignee: University of MassachusettsInventors: Sankaran Thayumanavan, Jiaming Zhuang
-
Patent number: 11642412Abstract: The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.Type: GrantFiled: September 6, 2018Date of Patent: May 9, 2023Assignee: W. L. Gore & Associates, Inc.Inventors: Robert L. Cleek, Edward H. Cully, Paul D. Drumheller, Theresa A. Holland
-
Patent number: 11623013Abstract: Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.Type: GrantFiled: November 10, 2020Date of Patent: April 11, 2023Inventors: Michael J. Smith, Haiying Tang, Paul E. Morin, Harold J. Malone, Luciano Mueller
-
Patent number: 11614443Abstract: Multiplex polymeric dye devices are provided. Aspects of the devices include a solid support, and first and second dried polymeric dye compositions distinctly positioned relative to a surface of the solid support. Aspects of the invention further include methods of making and using the devices, e.g., in analyte detection applications, as well as kits containing the devices.Type: GrantFiled: December 2, 2019Date of Patent: March 28, 2023Assignee: BECTON, DICKINSON AND COMPANYInventors: Marybeth Sharkey, Shumeye Mamo
-
Patent number: 11612660Abstract: Dendrimer compositions and methods for the treatment of one or more inflammatory and/or angiogenic diseases and/or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of the diseases of the eye, and/or for diagnosing the diseases and/or disorders of the eye. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be VEGFR tyrosine kinase inhibitors including sunitinib or analogues thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia/macrophages in retina/choroid.Type: GrantFiled: December 4, 2020Date of Patent: March 28, 2023Assignee: Ashvattha Therapeutics, Inc.Inventors: Jeffrey Cleland, Rishi Sharma, Santiago Appiani